Glucose lowering and vascular protective effects of cycloset added to GLP‐1 receptor agonists in patients with type 2 diabetes

Summary Objective To determine the glucose‐lowering mechanism of action and the effects of a quick‐release bromocriptine‐QR, a D2‐dopamine agonist (Cycloset) on vascular function in patients with type 2 diabetes (T2D). Study design and methods Fifteen poorly controlled T2D treated with metformin plu...

Full description

Saved in:
Bibliographic Details
Published in:Endocrinology, diabetes & metabolism diabetes & metabolism, 2018-10, Vol.1 (4), p.e00034-n/a
Main Authors: Alatrach, Mariam, Agyin, Christina, Adams, John, Chilton, Robert, Triplitt, Curtis, DeFronzo, Ralph A., Cersosimo, Eugenio
Format: Article
Language:English
Subjects:
bromocriptine
Cardiovascular disease
Diabetes
Dopamine
GLP-1 receptor agonists
Glucose
glucose efficacy
Hyperglycemia
Hypertension
Insulin resistance
Metabolism
Original
vascular protection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Objective To determine the glucose‐lowering mechanism of action and the effects of a quick‐release bromocriptine‐QR, a D2‐dopamine agonist (Cycloset) on vascular function in patients with type 2 diabetes (T2D). Study design and methods Fifteen poorly controlled T2D treated with metformin plus glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) were studied after 4 months of Cycloset, 3.2 mg/d. Subjects received a 5‐hour double‐tracer (iv 3‐3H‐glucose and oral 14C‐glucose) mixed meal test (MMT) to quantitate rates of endogenous glucose production (EGP), oral glucose appearance (RaO) and disappearance (Rd) pre‐ and post‐Cycloset. Vascular assessments included 2‐day continuous BP monitoring, reactive hyperaemia index (RHI) and arterial stiffness (AS). Results HbA1c decreased from 8.3 ± 0.3% to 7.7 ± 0.2% (P 
ISSN:2398-9238
2398-9238
DOI:10.1002/edm2.34